GlassScriptPhysician profile
Kathleen M Mullane
NPI 1831251388
$58,944.91
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $9,061 · 2021: $6,953 · 2022: $1,109.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $28,692.64 | 2019-2022 | |
| Glaxosmithkline, LLC. | $10,946.14 | 2019-2023 | |
| Gilead Sciences, INC. | $5,252.75 | 2020-2021 | |
| Adma Biomanufacturing LLC | $5,000.00 | 2019 | |
| Paratek Pharmaceuticals, INC. | $4,822.95 | 2019 | |
| Astellas Pharma US INC | $2,035.68 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $1,200.00 | 2021 | |
| Abbvie INC. | $994.75 | 2021 |
10 companies reported research payments only; those appear in the research section below.
Research and ownership
$3,594.88 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Mullane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.